SOLESENCE, INC.
About SOLESENCE, INC.
Solesence Inc is a health-oriented, science-driven company, focused on various skin health, beauty and wellness markets. Its primary skin health products are fully developed prestige skin care formulations with mineral-based UV protection enabled by proprietary Active Pharmaceutical Ingredients, which are also marketed as APIs for sale to manufacturers of other types of skin health products, including sunscreens and daily care products. Additionally, it continues to sell products in legacy markets, including medical diagnostics, architectural coatings, industrial coating applications, abrasion-resistant additives, and plastics additives applications. The company operates as a single business segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $62.1M
- Net income
- $1.8M
- Total assets
- $50.1M
- Market cap
- $92.5M
- Gross margin
- 25.9%
- Operating margin
- 2.5%
- Net margin
- 2.9%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $62.1M
- Cost of revenue
- $46.0M
- Gross profit
- $16.1M
- Operating expenses
- $14.5M
- Operating income
- $1.6M
- Income tax
- $73.0K
- Net income
- $1.8M
- EPS (basic)
- $0.03
- EPS (diluted)
- $0.02
Balance sheet
- Total assets
- $50.1M
- Current assets
- $28.8M
- Total liabilities
- $32.4M
- Current liabilities
- $13.9M
- Shareholders’ equity
- $17.6M
Cash flow
- Operating cash flow
- -$8.6M
- Investing cash flow
- -$2.1M
- Financing cash flow
- $10.6M
- Net cash flow
- -$121.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $92.5M
- P/E ratio
- 60.0
- EPS (diluted)
- $0.02
- Shares outstanding
- 77.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 26, 1997
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $1.8M in FY2025.
- Gross margin of 25.9%, net margin 2.9%.
- Trading 77% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 60.0.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review SOLESENCE, INC..
Write a review
News about SOLESENCE, INC.
News & sentiment via Polygon.io
